key: cord-0760861-tckirkzn authors: Bjerregaard, A.; Laing, I. A.; Backer, V.; Sverrild, A.; Khoo, S.‐K.; Chidlow, G.; Sikazwe, C.; Smith, D. W.; Le Souëf, P.; Porsbjerg, C. title: High fractional exhaled nitric oxide and sputum eosinophils are associated with an increased risk of future virus‐induced exacerbations: A prospective cohort study date: 2017-05-09 journal: Clin Exp Allergy DOI: 10.1111/cea.12935 sha: 052b4670681874727a05ab76464dac46688411c2 doc_id: 760861 cord_uid: tckirkzn BACKGROUND: The major trigger of asthma exacerbations is infection with a respiratory virus, most commonly rhinovirus. Type 2 inflammation is known to be associated with an increased risk of exacerbations in general. Whether type 2 inflammation at baseline increases the risk of future virus‐induced exacerbations is unknown. OBJECTIVE: To assess whether type 2 inflammation is associated with an increased risk of virus‐induced exacerbations of asthma. METHODS: Stable asthmatics had spirometry, skin prick test, measurement of FeNO and sputum induced for differential cell counts. Patients were followed up for 18 months, during which they were assessed at the research unit when they had symptoms of an exacerbation. Nasal swabs collected at these assessments underwent viral detection by PCR. RESULTS: A total of 81 asthma patients were recruited, of which 22 (27%) experienced an exacerbation during the follow‐up period. Of these, 15 (68%) had a respiratory virus detected at exacerbation. Sputum eosinophils >1% at baseline increased the risk of having a subsequent virus‐induced exacerbation (HR 7.6 95% CI: 1.6‐35.2, P=.010) as did having FeNO >25 ppb (HR 3.4 95% CI: 1.1‐10.4, P=.033). CONCLUSION AND CLINICAL RELEVANCE: Established type 2 inflammation during stable disease is a risk factor for virus‐induced exacerbations in a real‐life setting. Measures of type 2 inflammation, such as sputum eosinophils and FeNO, could be included in the risk assessment of patients with asthma in future studies. Asthma is an inflammatory disease of the airways characterised by variable airflow obstruction and hyperresponsiveness and is one of the most frequent chronic diseases of young adults. Acute exacerbations are the main cause of morbidity and healthcare utilisation 1 and thus preventing future exacerbations is a key goal in the clinical management of patients with asthma. Infection with respiratory viruses, particularly rhinoviruses (RV), is a common trigger of asthma exacerbations, but the mechanisms are still unclear. [2] [3] [4] Airway epithelial cells cultured ex vivo from nonasthmatic subjects produce TSLP, IL-25 and IL-33 in response to within 24 hours of contact with the study team. Exacerbations were defined as increased symptoms that required a change in medication as judged by the attending physician, in line with ATS/ERS recommendations. 21 Exacerbations managed by adjusting inhaled therapies were recorded as mild/moderate, whereas exacerbations requiring a course of oral corticosteroids (OCS) or admission to hospital, were considered severe. 21 In addition, patients were instructed to perform a nasal swab at home, when experiencing symptoms of a common cold-patients were not examined further on this occasion. The local scientific ethics committee approved the study (journal nr: H-3-2011-121). All subjects were informed and gave written consent. Spirometry (EasyOne, NDD, Switzerland) was completed according to ERS recommendations, 22 using NHANES III as the reference. 23 A skin prick test (Soluprick, ALK, Denmark) was completed, and atopy was defined as a positive test (maximum wheal diameter ≥3 mm) to at least one of ten common aeroallergens (grasses, house dust mite, birch, mugwort, dog, cat, horse, cladosporum herbarum and alternaria tenuis). Fractional expiratory nitric oxide (FeNO) was analysed on a NioxMinor (Aerocrine, Solna, Sweden) following the recommendations of the ERS and ATS 24 using the mean of two measurements. The ATS-defined cut-off of 25 ppb of FeNO was used to define patients with high and low FeNO. Sputum was induced according to the ERS guidelines and processed using a protocol described by Pavord et al. 25 Differential cell counts from cytospins were obtained from 400 non-squamous cells. A cut-off of 1% for sputum eosinophils was applied to define those with high and low sputum eosinophils, as it has been reported to correspond to the 95th percentile of sputum eosinophils in healthy adults. 26 Blood samples were assessed by the hospital clinical service and included a full white blood cell differential count and measurement of C-reactive protein (CRP) as well as total IgE (Cobas 8000; Roche, Basel, Switzerland). Asthma control was assessed with the Asthma Control Questionnaire (ACQ). 27 Nasal swabs (Copan Italia) were used to sample nasal fluid and tested using a tandem multiplex real-time PCR assay detecting a comprehensive range of respiratory viruses: Human adenovirus species B-D; human bocavirus; coronaviruses OC43, 229E, HKU1 and NL63; influenza viruses A, B and C; parainfluenza viruses 1-4; KI and WU polyomaviruses; respiratory syncytial virus types A and B and human metapneumovirus. 28, 29 RV was detected by a PCR directed at sequences in the 5 0 UTR genome of RV, and the products were identified to species level as RV-A, RV-B or RV-C by sequencing of this 260 bp product and alignment to known RV sequences using ClustalX software. 30 The data were analysed with SPSS version 22.0 (IBM SPSS, Armonk, NY, USA). Normally distributed data are reported as meanAEstandard deviation and analysed using student's t test for continuous variables, and chi-squared test for categorical variables. Log-transformed variables are reported as geometric mean (GM) with 95% CI. Non-normally distributed data (eg, cell counts) are reported as median (range), and comparisons were made using Kruskal-Wallis test. To assess the ability of baseline characteristics to predict risk of exacerbation, a proportional hazards model (Cox regression) was used and adjusted for predefined potential confounders of exacerbation risk, including ICS dose, smoking status, ACQ score and % predicted FEV1 (forced expiratory volume in the first second of expiration) at baseline. As the inflammatory markers examined (FeNO, sputum eosinophils) are highly correlated (both in previous studies and in our data), each marker was tested separately in to avoid multicollinearity. For all analyses a P-value of <.05 was considered significant. A total of 112 patients were approached, of which 81 patients agreed to participate ( Figure 1 ). ICS were taken by 73% of patients, with the remaining 27% using short acting beta2-agonists alone. In 18 of the 81 recruited patients (22%), FeNO was elevated at baseline (>25 ppb), and among the 56 patients able to produce a valid sputum sample, 16 patients (20%) had sputum eosinophils >1%. Eight patients had both high FeNO and high sputum eosinophils. The clinical characteristics of study subjects are described in Table 1 . Two patients were treated with antibiotics for suspected bacterial pneumonia, although bacterial cultures were later found to be negative. Patient characteristics, including age, sex and smoking status, were not different between those that had an exacerbation and those who did not (Table 1 ). In the exacerbation group, mean FeNO at baseline was higher (24 ppb 95% CI: 17-33, P=.048) compared to the non-exacerbation group (18 ppb 95% CI: [16] [17] [18] [19] [20] . Exacerbation patients also had a higher ACQ score at baseline (1.4AE1.1, P=.011) compared to the non-exacerbation patients (0.8AE0.9). There was a trend for lower prevalence of atopy in the exacerbation group (46% vs 68%, P=.066). Lung function, ICS dose and both sputum and blood differential cell counts were similar between the groups ( Figure 3 ). Proportional hazards models were constructed adjusting for known determinants of exacerbation risk (amount of ICS usage, current smoking, ACQ score and % predicted FEV1) at baseline. All demographic variables (sex, age, BMI) had a P-value >.3 in univariate analyses and were not included in the models. Each inflammatory marker was assessed separately for predicting risk of exacerbation (summarised in Table 2 ). There were too few patients in the virusnegative group for this analysis. Other potentially relevant risk factors relating to type 2 inflammation were also examined with adjustment for the same potential confounders as above: Atopic status, blood eosinophils >150910 9 cells/L and total IgE >150910 3 IU. None of these variables predicted the risk of exacerbation (Table 2) . In this study, both FeNO >25 ppb and sputum eosinophils >1% were associated with an increased risk of developing a virus-induced T A B L E 1 Baseline characteristics of patients who developed an exacerbation during follow-up (n=22) and those who did not experience any exacerbations (n=59) Had no exacerbation (n=59) P-value [13] [14] [15] to our knowledge, this is the first study to assess type 2 airway inflammation as a risk factor specifically for virusinduced asthma exacerbations. A synergistic effect of allergic sensitisation and viral infection on risk of hospital admission has been described in children. 35 In our study, we did not observe an increased risk of exacerbation (viral or non-viral) in patients sensitised to common aeroallergens, indicating that this association might be more pronounced in paediatric populations. Studies have found that cross-linking of the high affinity IgEreceptor (FceR1) results in blunted interferon responses to RV, 36, 37 which in turn is associated with ineffective viral clearing 38 and more pronounced asthma symptoms. 39, 40 Furthermore, the anti-IgE antibody omalizumab has been shown to eliminate the return-to-school peaks of exacerbations in a large cohort of asthmatic children, suggestive of a reduction of virus-induced exacerbations. 12 Taken together this indicates that high IgE might play a role in virusinduced asthma exacerbations; however, in our study, high IgE was not associated with an increased risk of virus-induced exacerbations. With the advent of further antibody treatment options in the coming years, there is a widespread intent to enhance personalised asthma management, by tailoring medication choice and dosage according to the inflammatory phenotype. These treatments are likely to prevent some, but not all, exacerbations. Given that respiratory viruses are a major trigger of exacerbations, understanding how each pathway of airway inflammation influences the risk of virus-induced exacerbation will be a critical step in understanding how to optimise the use of antibody therapies to achieve the best individual patient outcomes. In conclusion, we have shown that high FeNO and sputum eosinophils at baseline are risk factors for virus-induced exacerbations in a real-life setting. If confirmed in larger studies, this could have implications on the risk assessment of asthma patients. The study was funded by Bispebjerg University Hospital, the University of Copenhagen and by an unrestricted grant from the Lundbeck Foundation. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study Respiratory viruses and exacerbations of asthma in adults Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection NK cell deficiency predisposes to viral-induced Th2-type allergic inflammation via epithelial-derived IL-25 IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo The interleukin-33 receptor ST2 is important for the development of peripheral airway hyperresponsiveness and inflammation in a house dust mite mouse model of asthma IL-33 and thymic stromal lymphopoietin mediate immune pathology in response to chronic airborne allergen exposure Virus-induced eosinophil mediator release requires antigen-presenting and CD4+ T cells Role of atopic status in Toll-like receptor (TLR)7-and TLR9-mediated activation of human eosinophils Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations Elevated exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids Symptom-and fraction of exhaled nitric oxide-driven strategies for asthma control: a cluster-randomized trial in primary care Frequent exacerbators-a distinct phenotype of severe asthma Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial Anti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized, controlled trial Lebrikizumab in moderateto-severe asthma: pooled data from two randomised placebocontrolled studies An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice Standardisation of spirometry Spirometric reference values from a sample of the general US population ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide The use of induced sputum to investigate airway inflammation Inflammatory subtypes in asthma: assessment and identification using induced sputum Development and validation of a questionnaire to measure asthma control An economical tandem multiplex real-time PCR technique for the detection of a comprehensive range of respiratory pathogens Respiratory viral pathogens associated with lower respiratory tract disease among young children in the highlands of Papua New Guinea A diverse group of previously unrecognized human rhinoviruses are common causes of respiratory illnesses in infants Improved molecular typing assay for rhinovirus species A, B, and C Mepolizumab treatment in patients with severe eosinophilic asthma Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children Rhinovirus 16-induced IFN-α and IFN-β are deficient in bronchoalveolar lavage cells in asthmatic patients Rhinovirus-induced PBMC responses and outcome of experimental infection in allergic subjects Role of deficient type III interferon-k production in asthma exacerbations Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection High fractional exhaled nitric oxide and sputum eosinophils are associated with an increased risk of future virus-induced exacerbations: A prospective cohort study The authors declare no conflict of interest.